268 related articles for article (PubMed ID: 23787997)
1. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.
Sukkurwala AQ; Martins I; Wang Y; Schlemmer F; Ruckenstuhl C; Durchschlag M; Michaud M; Senovilla L; Sistigu A; Ma Y; Vacchelli E; Sulpice E; Gidrol X; Zitvogel L; Madeo F; Galluzzi L; Kepp O; Kroemer G
Cell Death Differ; 2014 Jan; 21(1):59-68. PubMed ID: 23787997
[TBL] [Abstract][Full Text] [Related]
2. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
3. Probing the role of CXC motif in chemokine CXCL8 for high affinity binding and activation of CXCR1 and CXCR2 receptors.
Joseph PR; Sarmiento JM; Mishra AK; Das ST; Garofalo RP; Navarro J; Rajarathnam K
J Biol Chem; 2010 Sep; 285(38):29262-9. PubMed ID: 20630874
[TBL] [Abstract][Full Text] [Related]
4. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases.
Russo RC; Garcia CC; Teixeira MM; Amaral FA
Expert Rev Clin Immunol; 2014 May; 10(5):593-619. PubMed ID: 24678812
[TBL] [Abstract][Full Text] [Related]
5. Phylogenetic conservation of the preapoptotic calreticulin exposure pathway from yeast to mammals.
Madeo F; Durchschlag M; Kepp O; Panaretakis T; Zitvogel L; Fröhlich KU; Kroemer G
Cell Cycle; 2009 Feb; 8(4):639-42. PubMed ID: 19182525
[TBL] [Abstract][Full Text] [Related]
6. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.
Maxwell PJ; Neisen J; Messenger J; Waugh DJ
Oncotarget; 2014 Jul; 5(13):4895-908. PubMed ID: 24970800
[TBL] [Abstract][Full Text] [Related]
7. Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer.
Wilson C; Maxwell PJ; Longley DB; Wilson RH; Johnston PG; Waugh DJ
PLoS One; 2012; 7(5):e36545. PubMed ID: 22590561
[TBL] [Abstract][Full Text] [Related]
8. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death.
Panaretakis T; Joza N; Modjtahedi N; Tesniere A; Vitale I; Durchschlag M; Fimia GM; Kepp O; Piacentini M; Froehlich KU; van Endert P; Zitvogel L; Madeo F; Kroemer G
Cell Death Differ; 2008 Sep; 15(9):1499-509. PubMed ID: 18464797
[TBL] [Abstract][Full Text] [Related]
9. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.
Gabellini C; Trisciuoglio D; Desideri M; Candiloro A; Ragazzoni Y; Orlandi A; Zupi G; Del Bufalo D
Eur J Cancer; 2009 Sep; 45(14):2618-27. PubMed ID: 19683430
[TBL] [Abstract][Full Text] [Related]
10. The nerve growth factor alters calreticulin translocation from the endoplasmic reticulum to the cell surface and its signaling pathway in epithelial ovarian cancer cells.
Vera CA; Oróstica L; Gabler F; Ferreira A; Selman A; Vega M; Romero CA
Int J Oncol; 2017 Apr; 50(4):1261-1270. PubMed ID: 28260038
[TBL] [Abstract][Full Text] [Related]
11. CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer.
Li E; Yang X; Du Y; Wang G; Chan DW; Wu D; Xu P; Ni P; Xu D; Hu Y
Front Immunol; 2021; 12():667177. PubMed ID: 34025668
[TBL] [Abstract][Full Text] [Related]
12. Biphasic Increases of Cell Surface Calreticulin Following Treatment with Mitoxantrone.
Azuma Y; Suzuki K; Higai K; Matsumoto K; Tada S
Biol Pharm Bull; 2020 Oct; 43(10):1595-1599. PubMed ID: 32727970
[TBL] [Abstract][Full Text] [Related]
13. An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer.
Mishra A; Suman KH; Nair N; Majeed J; Tripathi V
Mol Biol Rep; 2021 Sep; 48(9):6551-6561. PubMed ID: 34426905
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
15. Probiotics improve re-epithelialization of scratches infected by Porphyromonas gingivalis through up-regulating CXCL8-CXCR1/CXCR2 axis.
Albuquerque-Souza E; Ishikawa KH; Amado PP; Nicoli JR; Holzhausen M; Mayer MPA
Anaerobe; 2021 Dec; 72():102458. PubMed ID: 34547426
[TBL] [Abstract][Full Text] [Related]
16. The CXCL8-CXCR1/2 pathways in cancer.
Liu Q; Li A; Tian Y; Wu JD; Liu Y; Li T; Chen Y; Han X; Wu K
Cytokine Growth Factor Rev; 2016 Oct; 31():61-71. PubMed ID: 27578214
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.
Maxwell PJ; Coulter J; Walker SM; McKechnie M; Neisen J; McCabe N; Kennedy RD; Salto-Tellez M; Albanese C; Waugh DJ
Eur Urol; 2013 Aug; 64(2):177-88. PubMed ID: 22939387
[TBL] [Abstract][Full Text] [Related]
18. ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin.
Obeid M
J Immunol; 2008 Aug; 181(4):2533-43. PubMed ID: 18684944
[TBL] [Abstract][Full Text] [Related]
19. The antagonist of CXCR1 and CXCR2 protects
Cui S; Qiao L; Yu S; Men L; Li Y; Li F; Du J
Am J Physiol Endocrinol Metab; 2019 Dec; 317(6):E1205-E1217. PubMed ID: 31573846
[TBL] [Abstract][Full Text] [Related]
20. The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.
Yamamura Y; Tsuchikawa T; Miyauchi K; Takeuchi S; Wada M; Kuwatani T; Kyogoku N; Kuroda A; Maki T; Shichinohe T; Hirano S
Int J Clin Oncol; 2015 Apr; 20(2):386-94. PubMed ID: 24972573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
